Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A global phase 2 trial of ZF-874

Trial Profile

A global phase 2 trial of ZF-874

Status: Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 18 Aug 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ZF 874 (Primary)
  • Indications Alpha 1-antitrypsin deficiency
  • Focus Therapeutic Use
  • Most Recent Events

    • 10 Aug 2022 Status changed from planning to withdrawn prior to enrolment as per Centessa Pharmaceuticals media release
    • 10 Aug 2022 According to a Centessa Pharmaceuticals media release, Company today announced its decision to discontinue development of ZF874 following a recent report of an adverse event (AE) involving elevated liver enzymes (AST/ALT) in a PiMZ subject dosed with 5 mg/kg BID of ZF874 in the Phase 1 study.
    • 15 Nov 2021 According to a Centessa Pharmaceuticals media release, the company anticipates starting this global Phase 2 study in 2Q 2022, with 6-month dosing to commence in 2H 2022.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top